Fund Manager Summary on Paragon Care Ltd (ASX:PGC)
In December 2025, Tamim Funds Management commented that Paragon Care Ltd (ASX:PGC) reported multiple material developments, including completion of the Somnotec acquisition, agreement to buy Haju Medical for A$70 million (A$30m upfront plus contingent consideration) with Haju generating approximately A$30m of revenue and A$7.7m of EBITDA in FY24 and expected to be earnings accretive from FY26, the appointment of Brendon Pentland as CFO, and active management of exposure to administrators of 54 Infinity Retail Pharmacies while the share price traded around $0.22. On balance, the commentary signals a strategic push to accelerate regional expansion and broaden product and service offerings across Southeast Asia, creating potential structural tailwinds and targeted earnings accretion from the Haju acquisition, but it also highlights near-term execution and capital deployment risks — integration complexity from multiple acquisitions, contingent consideration obligations, and counterparties entering administration that could affect cash flow and working capital — which the new CFO and ongoing engagement with administrators are intended to mitigate; investors should therefore weigh the growth opportunity from expanded distribution and higher-margin product mix against integration execution risk, contingent payment exposure, and short-term market and counterparty pressures.
Commentary From The Managers
There are 4 insights from 4 fund managers regarding their investment in Paragon Care Ltd (ASX:PGC) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Paragon Care Ltd (ASX:PGC)?
Fund managers including Endeavor Asset Management, Forager Funds, Wilson Asset Management and Tamim Funds Management have invested in Paragon Care Ltd (ASX:PGC).
Why do fund managers invest in Paragon Care Ltd?
Fund managers invest in Paragon Care Ltd due to its robust position in the healthcare distribution sector, highlighted by a recent merger with fast-growing CH2 Holdings. This merger significantly enhances Paragon's revenue base and market share potential, promising continued growth in an essential industry. The company trades at a lower valuation compared to peers, offering an attractive risk/reward profile. Furthermore, expected synergies from the merger, alongside improving financial performance, support a favorable investment thesis.
What happened to Paragon Care Ltd (ASX:PGC)?
There have been no recent updates from fund managers regarding Paragon Care Ltd although fund managers including Endeavor Asset Management, Forager Funds and Wilson Asset Management have previously commented.
What is the short interest in Paragon Care Ltd (ASX:PGC)?
The short interest in Paragon Care Ltd (ASX:PGC) is 0.11% which makes it the 405th most shorted stock on the ASX. Of the 1.7B shares that Paragon Care Ltd has on issue, 1.9M have been sold short.
What does Paragon Care Ltd (ASX:PGC) do?
Paragon Care Ltd. engages in supplying medical equipment to the health and aged care markets. It operates through the following segments: Diagnostic and Scientific, Devices, Capital and Consumables, and Service and Technology. The Diagnostic and Scientific segment is involved in blood bank diagnostics manufacturer, clinical pathology diagnostics distribution, and scientific and research and development laboratory equipment distribution. The Devices segment focuses on ophthalmology and optometry, orthopedics, pain management, infection prevention, and OrthoBiologics. The Capital and Consumables segment offers medical, surgical, and veterinary services. The Service and Technology segment refers to offering biomedical devices to capital equipment, service support and technology management, and service partnership brands. The company was founded in 1994 and is headquartered in Mt. Waverley, Australia.